| Literature DB >> 30626153 |
Yue Yang1,2,3,4, Ronge Xing5,6,7, Song Liu8,9,10, Yukun Qin11,12,13, Kecheng Li14,15,16, Huahua Yu17,18,19, Pengcheng Li20,21,22.
Abstract
Chitooligosaccharides (COS), the hydrolyzed products of chitin and chitosan, can be obtained by various methods. In this study, water-soluble COS were prepared from α- and β-chitosan by microwave-assisted degradation and their immunostimulatory effects were investigated in RAW 264.7 macrophages. The results indicated that α-COS were more active than β-COS in promoting the production of nitric oxide (NO) and cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin 6 (IL-6). Quantitative real-time reverse transcription polymerase chain reaction and Western blotting indicated that COS also enhanced the expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and TNF-α. Further analyses demonstrated that COS induced the phosphorylation of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), p38, p85 and Akt, and the nuclear translocation of p65, indicating that they are able to activate the mitogen-activated protein kinases (MAPKs) and phosphoinositide 3-kinases (PI3K)/Akt signaling pathways dependent on nuclear factor (NF)-κB activation. In conclusion, COS activate RAW 264.7 cells via the MAPK and PI3K/Akt signaling pathways and are potential novel immune potentiators.Entities:
Keywords: RAW 264.7 cells; chitooligosaccharide; immunostimulatory activity; mitogen-activated protein kinases (MAPK), phosphoinositide 3-kinases (PI3K)/Akt
Mesh:
Substances:
Year: 2019 PMID: 30626153 PMCID: PMC6357175 DOI: 10.3390/md17010036
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Fourier-transform infrared (FT-IR) spectra of chitosan and chitooligosaccharide (COS). The molecular weights were as follows: α-chitosan (1856 kDa), β-chitosan (4574 kDa), α-COS (1874 Da) and β-COS (2186 Da).
Figure 21H NMR and 13C NMR spectra of chitosan and chitooligosaccharide (COS). (A) 1H NMR spectrum of α-chitosan (1856 kDa). (B) 1H NMR spectrum of β-chitosan (4574 kDa). (C) 1H NMR spectrum of α-COS (1874 Da). (D) 1H NMR spectrum of β-COS (2186 Da). (E) 13C NMR spectrum of α-chitosan (1856 kDa). (F) 13C NMR spectrum of β-chitosan (4574 kDa). (G) 13C NMR spectrum of α-COS (1874 Da). (H) 13C NMR spectrum of β-COS (2186 Da).
Figure 3The effects of chitooligosaccharides (COS) on cell viability and cytokine production. RAW 264.7 cells were treated with COS (0–200 μg/mL) for 24 h. (A) The nitric oxide production on treatment with α-COS (1874 Da). (B) The cell viability on treatment with α-COS (1874 Da). (C) The production of tumor necrosis factor-α (TNF-α) on treatment with α-COS (1874 Da). (D) The production of interleukin-6 (IL-6) on treatment with α-COS (1874 Da). The values are presented as means ± SD (n = 3). (* p < 0.05 vs. control group).
Figure 4Effects of COS on the expression of cytokines in RAW 264.7 cells at the gene and protein levels. (A) Gene expression of inducible nitric oxide synthase (iNOS), TNF-α, IL-6, and cyclooxygenase (COX)-2 in RAW264.7 cells determined by real-time reverse transcription polymerase chain reaction after stimulation with 100 μg/mL COS (1874 Da). The expression data were normalized to glyceraldehyde 3-phosphate dehydrogenase and shown as fold-changes relative to the control (presented as means ± SD) (* p < 0.05 vs. control group). (B) The effects of 100 μg/mL COS (1874 Da) on the protein expression levels of TNF-α, iNOS, and COX-2.
Figure 5Determination of COS-induced signaling pathways. RAW 264.7 cells were stimulated with 100 μg/mL COS (1874 Da) for the indicated times (0–360 min). Then, cell proteins were extracted and subjected to Western blotting. The effects of COS (1874 Da) on the NF-κB p65 (A), MAPK (B), IKKα/β and IκBα (C), PI3K-Akt (D) signaling pathways were determined. The relative expression levels of protein were normalized by β-actin. (E) NO production in RAW 264.7 cells pretreated with or without inhibitors after stimulated with 100 μg/mL COS. Data are presented as mean ± SD. (* p < 0.05 vs. COS-treated group).